^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PVX-410

    i
    Other names: XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410, PVX 410, PVX-410
    Associations
    News

    Trials

    Company:
    OncoPep
    Drug class:
    CS-1 inhibitor, CD138 inhibitor, XBP1 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer (NCT02826434)
    Phase 1
    Massachusetts General Hospital
    Active, not recruiting
    Last update posted :
    09/23/2024
    Initiation :
    08/01/2016
    Primary completion :
    06/01/2025
    Completion :
    09/01/2026
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • Hiltonol (poly-ICLC) • PVX-410
    PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer (NCT03362060)
    Phase 1
    Massachusetts General Hospital
    Active, not recruiting
    Last update posted :
    09/23/2024
    Initiation :
    12/12/2017
    Primary completion :
    07/30/2025
    Completion :
    06/30/2026
    HER-2 • ER • PGR
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • PVX-410
    Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer (NCT04634747)
    Phase 2
    OncoPep, Inc.
    Not yet recruiting
    Last update posted :
    04/20/2022
    Initiation :
    04/30/2022
    Primary completion :
    04/01/2023
    Completion :
    04/01/2025
    PD-L1
    |
    PD-L1 expression • HLA-A2 positive
    |
    Keytruda (pembrolizumab) • PVX-410